Current Architectural and Developmental Approaches in Artificial Intelligence Models for Prostate Cancer Detection and Management: A Technical Report

TL;DR

This report reviews how AI is improving prostate cancer detection and grading, offering more accurate and efficient diagnostic tools compared to traditional methods.

Contribution

The report provides an overview of current AI models and techniques for prostate cancer diagnostics, emphasizing their potential to enhance diagnostic accuracy and workflow efficiency.

Findings

AI models using convolutional neural networks and deep learning improve tumor detection and Gleason grading accuracy.

AI integration with PSA data enhances risk stratification and reduces unnecessary biopsies.

Challenges like inconsistent data and imaging domain shifts remain barriers to AI adoption in clinical practice.

Abstract

Prostate cancer is a prevalent malignancy among men and remains a major cause of cancer-related mortality. The increasing incidence of cases underscores the need for advancements in diagnostic methodologies. Artificial intelligence (AI) is emerging as a transformative tool in addressing challenges in prostate cancer diagnostics, particularly in the analysis of histopathological whole-slide images and the refinement of algorithmic Gleason grading. Traditional diagnostic approaches, including the Gleason grading system and prostate-specific antigen (PSA) testing, are subject to variability and inefficiencies, placing a significant burden on pathologists and potentially delaying accurate diagnoses. This report explores the role of AI-driven models, such as convolutional neural networks and clinically validated deep learning systems, in enhancing diagnostic accuracy for tumor detection and Gleason grading. These models incorporate advanced techniques, including ensemble learning, specialized pooling mechanisms, and semi-supervised learning, to improve efficiency in feature extraction. Additionally, AI models integrating PSA data have demonstrated improved accuracy in risk stratification, reducing the reliance on traditional PSA thresholds and minimizing unnecessary biopsies. However, challenges persist, such as inconsistencies in data sources, imaging domain shifts, and the absence of standardized stain normalization, which hinder AI’s widespread clinical adoption. By examining the current technological landscape, this report highlights AI’s potential to revolutionize prostate cancer diagnostics, enhancing workflow efficiency and diagnostic precision in clinical practice.